CSPC Pharmaceutical Group Ltd
Company Profile
Business description
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
Contact
No.896 Zhongshandong Street
Gaoxin District
Hebei Province
Shijiazhuang050035
CHNT: +86 31187037015
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
19,700
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
stocks
Avoid this overvalued ASX lithium producer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.60 | 54.00 | -0.60% |
| CAC 40 | 8,442.73 | 57.24 | 0.68% |
| DAX 40 | 25,049.52 | 309.16 | 1.25% |
| Dow JONES (US) | 52,573.99 | 725.09 | 1.40% |
| FTSE 100 | 10,550.54 | 88.91 | 0.85% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,415.83 | 60.81 | -0.24% |
| Nikkei 225 | 72,366.34 | 3,191.38 | 4.61% |
| NZX 50 Index | 13,493.05 | 92.39 | 0.69% |
| S&P 500 | 7,393.20 | 34.98 | 0.48% |
| S&P/ASX 200 | 8,748.70 | 51.90 | -0.59% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |